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ABSTRACT
Objective Examine the effect of tamoxifen and 
aromatase inhibitors (AIs) on the risk of 12 clinically 
relevant cardiovascular outcomes in postmenopausal 
female breast cancer survivors.
Methods We carried out two prospective cohort studies 
among postmenopausal women with breast cancer in 
UK primary care and hospital data (2002–2016) and US 
Surveillance, Epidemiology and End Results- Medicare 
data (2008–2013). Using Cox adjusted proportional 
hazards models, we compared cardiovascular risks 
between AI and tamoxifen users; and in the USA, 
between users of both drug classes and women receiving 
no endocrine therapy.
Results 10 005 (UK) and 22 027 (USA) women with 
postmenopausal breast cancer were included. In both 
countries, there were higher coronary artery disease risks in 
AI compared with tamoxifen users (UK age- standardised 
incidence rate: 10.17 vs 7.51 per 1000 person- years, HR: 
1.29, 95% CI 0.94 to 1.76; US age- standardised incidence 
rate: 36.82 vs 26.02 per 1000 person- years, HR: 1.29, 
95% C I1.06 to 1.55). However, comparisons with those 
receiving no endocrine therapy (US data) showed no higher 
risk for either drug class and a lower risk in tamoxifen users 
(age- standardised incidence rate tamoxifen vs unexposed: 
26.02 vs 35.19 per 1000 person- years, HR: 0.74, 95% 0.60 
to 0.92; age- standardised incidence rate AI vs unexposed: 
36.82 vs 35.19, HR: 0.96, 95% CI 0.83 to 1.10). Similar 
patterns were seen for other cardiovascular outcomes 
(arrhythmia, heart failure and valvular heart disease). 
As expected, there was more venous thromboembolism 
in tamoxifen compared with both AI users and those 
unexposed.
Conclusions Higher risks of several cardiovascular 
outcomes among AI compared with tamoxifen users 
appeared to be driven by protective effects of tamoxifen, 
rather than cardiotoxic effects of AIs.
BACKGROUND
Oestrogen or progesterone receptor positive breast 
cancer (ER/PR+) accounts for 83% of all breast 
cancer, and endocrine therapies are recommended to 
minimise risk of recurrence.1 2 Since 2006, aromatase 
inhibitors (AIs) have been recommended over tamox-
ifen for postmenopausal women due to greater effi-
cacy.3 However, it has recently been suggested that AI 
users have a higher risk of subsequent cardiovascular 
disease (CVD) compared with tamoxifen users.4 It is 
in unclear whether this reflects cardiotoxicities of AIs 
or a protective effect of tamoxifen.
Tamoxifen inhibits the growth of breast tumours 
through competitive antagonism of oestrogen at 
its receptor. It is known that oestrogen agnostic 
effects of tamoxifen lowers total serum cholesterol 
by 10%–20% and low- density lipoprotein levels by 
15%–22%, which could explain any protective effects 
of tamoxifen on the cardiovascular system.5–8 In 
contrast, the oestrogen- agonistic actions of tamoxifen 
result in a detrimental increase in thrombogenicity 
and increased risk of venous thrombosis and throm-
boembolism.9 AIs inhibit the conversion of the adrenal 
androgen substrate androstenedione to oestrogen in 
the breast tissue, reducing oestrogen production, and 
it has been hypothesised that the depletion of endog-
enous oestrogen production caused by AIs might 
increase the risk of CVD. A recent analysis of UK 
data observed higher risks of heart failure (HF) and 
possible higher risks of myocardial infarction (MI) 
and stroke in AI compared with tamoxifen users; it 
was suggested that the higher risks of cardiovascular 
events associated with AIs may therefore need to be 
taken account in treatment decisions.10 However, this 
study directly compared AIs and tamoxifen, and other 
evidence, summarised by a recent systematic review, 
has suggested that tamoxifen may have an underlying 
protective association with some CVD outcomes, 
making interpretation of the findings unclear.4
Using data on women with postmenopausal breast 
cancer from two large electronic medical record data-
sets, we therefore aimed to: (i) examine the consis-
tency of estimated associations between endocrine 
therapy drug class (AI/tamoxifen) and CVD risk 
between UK and US cohorts and (2) compare CVD 
risks between users of both drug classes and ER/PR+ 
breast cancer patients unexposed to endocrine therapy 
to investigate the key question of whether differences 
between the two drug classes were driven by under-
lying harmful or protective associations.
METHODS
Study design and data sources
We assembled two separate nationally represen-
tative cohorts of women with incident postmeno-
pausal breast cancer using prospectively collected 
data from the UK and USA. In the UK, we used 
Clinical Practice Research Datalink primary care 
data (CPRD) and linked Hospital Episode Statis-
tics (HES).11 In the USA, we used the Surveillance, 
Epidemiology, and End Results program (SEER) 
and Medicare linked database.12 Full data source 
details are in online supplemental appendix 1.
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Study populations
Differences in available data within the two cohorts are explained 
in online supplemental appendix 2.
UK cohort
We identified women with CPRD and HES data over 54 years 
(median age of the menopause in Europe13), with any incident 
breast cancer in CPRD (after at least 1 year of CPRD follow- up), 
who initiated AIs or tamoxifen in primary care after their diag-
nosis, from 1 January 2002 (date from which preliminary anal-
ysis showed that third- generation AIs came into widespread use) 
to 31 March 2016 (latest CPRD and HES linkage). Follow- up 
began at the latest of 1 year after breast cancer diagnosis or first 
AI or tamoxifen prescription (hereafter index date). Women 
were excluded if prior to their index date they: died, transferred 
out of CPRD, had any other cancer diagnosis or were diagnosed 
with the CVD event of interest (at any point prior to index date).
US cohort
We identified women over 65 years with incident ER/PR+ and 
stage 1–3 breast cancer and continuous Medicare Parts A, B and 
D enrolment (and no managed care coverage) for 12 months 
prior to the month of cancer diagnosis from 1 January 2008 
(Medicare Part D data are available from 2007) and 31 December 
2013 (last capture of cancer cases in SEER). Women with an 
endocrine therapy prescription prior to their breast cancer diag-
nosis were excluded. Follow- up began 1 year after the date of 
breast cancer (hereafter index date). Women were excluded if 
prior to their index date they: died, discontinued from Medi-
care Parts A, B or D, had any other cancer diagnosis or were 
diagnosed with the CVD event of interest (within a 3- year look 
back period to ensure likelihood of capturing a prior event was 
not dependent on age as Medicare follow- up starts at 65 years).
Exposure, outcomes and covariates
Tamoxifen and AI exposures were identified using prescription codes 
in the UK (available at https:// doi. org/ 10. 17037/ DATA. 177), and 
National Drug Codes and Healthcare Common Procedural Coding 
System (HCPCS) procedure codes in the USA (online supplemental 
appendix 3). Primary exposure was ever use of tamoxifen, ever use 
of AI or ever use of both drugs, with ever use defined as at least one 
prescription (UK) or fill (USA) of the endocrine therapy medica-
tion; the US study additionally included no exposure to any endo-
crine therapy (which did not exist in the UK study, because receipt 
of endocrine therapy was an inclusion criterion). Exposure was 
time- updated to indicate a woman had been exposed to both drugs 
if they switched endocrine therapies during follow- up. The baseline 
exposure group was classified as ever exposure to tamoxifen for 
the ever AI versus tamoxifen analyses in both the UK and USA. 
The baseline exposure group was also changed to no exposure to 
any endocrine therapy for the ever AI/tamoxifen versus unexposed 
analyses that was only possible in the USA. Visualisations of expo-
sure categorisations are shown in online supplemental appendix 4. 
The main CVD outcomes were: coronary artery disease (angina, 
MI, revascularisation procedures and sudden cardiac arrest); 
peripheral vascular disease; stroke; arrhythmia; HF (including 
cardiomyopathy); pericarditis; valvular heart disease (VHD); and 
venous thromboembolism (VTE) (deep vein thrombosis (DVT) and 
pulmonary embolism). Composite CVD outcomes and individual 
components of the composite outcomes were analysed separately. 
Events were identified through clinical diagnoses using NHS Read 
codes in the CPRD and International Classification of Disease 
(ICD), 10th edition codes in HES in the UK (available at https:// 
doi. org/ 10. 17037/ DATA. 177) and ICD-9 and HCPCS codes in the 
US study (online supplemental appendix 5).
In both studies, we adjusted for age, cardiovascular history 
and risk factors, use of cardioprotective medications, other 
comorbidities, time since index date and calendar year. In the 
UK, we were additionally able to adjust for smoking, alcohol, 
body mass index and index of multiple deprivation (ie, socio-
economic status); in the US study, we were additionally able to 
adjust for race, region and use of anticancer therapies (anthra-
cyclines, taxanes, trastuzumab and other systemic treatments). 
A full comparison of the covariates considered in the UK and 
USA is in online supplemental appendix 6. Algorithms to define 
confounders in the UK are in online supplemental appendix 7, 
and code lists used for variable definitions are at https:// doi. org/ 
10. 17037/ DATA. 177. Codes used to identify prescriptions in the 
US are in online supplemental appendix 8.
Statistical analysis
Observation began at index date and ended at the earliest of: a CVD 
event of interest; diagnosis of another (non- breast) cancer; death; 
and transfer out of CPRD/end of Medicare Parts A, B or D enrol-
ment. Observation could also end at the end of the study period, 
which was 31 March 2016 in UK and 31 December 2014 in USA.
Separate analyses were conducted in UK and USA and for 
each CVD outcome. Distributions of characteristics at index 
date were described. Number of events and crude incident 
rates of each outcome of interest by exposure were calculated. 
Cox proportional hazards models with an age timescale were 
fitted for each outcome of interest to obtain unadjusted HRs 
and 95% CIs for the association between endocrine therapy use 
and outcome; those with a diagnosis of the specific outcome of 
interest before the index date were excluded from the analysis 
for that outcome. All covariates were then added to obtain fully 
adjusted HRs. We then fitted interactions, with prespecified vari-
ables considered clinically important to investigate effect modi-
fication by current age (54–69 and 70+ years in the UK; 66–84 
and 85+ years in the USA); time since index date (0–1 years, 
1–3 years and 3+ years); and history of any CVD prior to index 
date (other than the CVD outcome of interest) for the coronary 
artery disease (composite), arrhythmia, stroke, pericarditis (USA 
only), HF, VHD and VTE (composite) outcomes (interactions 
were not investigated for other outcomes due to limited power). 
We statistically tested for interactions using likelihood ratio tests. 
Women with missing data (8.7% in the UK, and 5.1% in the 
USA) were excluded from all analyses (complete case analysis), 
which is valid in a regression context if missingness is condi-
tionally independent of the outcome.14 Unfortunately, this is an 
untestable assumption (as it includes conditioning on the missing 
values themselves), but this assumption is more plausible than 
the missing at random assumption required for multiple impu-
tation in the UK data; in the US data, it is possible that missing-
ness was either at random and conditionally independent of the 
outcome, but we used a complete case analysis in order to have 
a consistent approach across the UK and US studies. We also 
calculated age- standardised incidence rates for each outcome by 
fitting a Poisson regression model with exposure and age, setting 
all individuals to each level of exposure separately and predicting 
the number of events, then dividing by the total person- years.
Sensitivity analyses
The main analyses were repeated with the UK and US study popu-
lations and covariates modified to be as similar as possible (details 
in online supplemental appendix 9) A post hoc quantitative bias 
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analysis explored potential unmeasured confounding in the 
large estimated protective effect of tamoxifen use on the risk 
of MI (online supplemental appendix 10).15 Finally, the primary 
analysis in the US data was additionally adjusted adjuvant radio-
therapy to assess any additional confounding of the effect of 
endocrine therapy on the risk of CVD.
RESULTS
The UK study included 10 005 women, with 4716 (47%) initially 
prescribed tamoxifen and 5289 (53%) initially prescribed an AI 
(table 1, flow diagram in figure 1); the median person- years of 
follow- up in each exposure group was: ever tamoxifen: 2.3 years 
(IQR: 1.2–5.4 years), ever AI: 2.2 years (IQR: 0.9–4.3 years) 
and ever both: 3.5 years (IQR: 1.5–6.3 years). The US study 
included 22 027 women, with 4667 (22%), 2286 (10%) and 
15 074 (68%) initially filling no endocrine therapy, tamoxifen 
and an AI, respectively (table 2, flow diagram in figure 1); the 
median person- years of follow- up in each exposure group were 
as follows: unexposed: 1.6 years (IQR: 0.6–3.3 years), tamox-
ifen 2.2 years (IQR: 1.0–3.8 years), AI: 2.0 years (IQR: 0.9–3.6 
years) and both: 1.9 years (IQR: 0.8–3.5 years).
Ever AI versus tamoxifen use
In both the UK and USA, there was a higher observed rate of most 
CVDs, excluding VTE outcomes, among those ever exposed to an 
AI compared with tamoxifen (online supplemental appendices 11 
and 12). In adjusted analyses, there was evidence of a higher risk 
of HF in AI compared with tamoxifen users in the UK (HR: 1.68, 
95% CI 1.24 to 2.26; figure 2), which was not replicated in the 
USA (HR: 0.96, 95% CI 0.83 to 1.12). Other adjusted HRs were 
consistent between the two settings; there was evidence in one or 
both settings that AI users compared with tamoxifen users had 
higher risk of coronary artery disease, MI, arrhythmia, pericarditis 
and VHD (HRs ranged from 1.29 to 3.25 in the UK, and 1.21 to 
1.81 in the USA; figure 2) and lower risk of DVT (UK HR: 0.63, 
95% 0.43 to 0.93; US HR: 0.81, 95% CI 0.50 to 1.09).
Ever AI/tamoxifen use versus unexposed
The US study included women without exposure to either endo-
crine therapy; observed rates of most CVDs, excluding VTE, 
were lower in both the tamoxifen and AI groups compared with 
the unexposed group, while VTE outcome rates were higher 
in the endocrine therapy groups (Appendix 12). The patterns 
were similar in adjusted analyses (figure 3); there was evidence 
that tamoxifen users had lower risks than unexposed women 
for coronary artery disease, MI, stroke, arrhythmia, pericarditis 
and VHD (HRs ranged from 0.37 to 0.87); HR point estimates 
for AI users versus unexposed were also in the protective direc-
tion for all non- VTE CVD outcomes, but in mostly closer to the 
null than for tamoxifen, and with confidence intervals including 
no association. There was weak evidence of higher risk VTE in 
tamoxifen users compared with the unexposed (HR: 1.39, 95% 
CI 0.98 to 1.98) but little evidence of a difference for AI users 
versus unexposed (HR: 1.14, 95% Ci 0.86 to 1.52).
Effect modification
There was no strong evidence of effect modification by age, 
time since index date or prior CVD in the UK or USA (online 
supplemental appendices 13 and 14), though there were few 
events within strata, limiting precision. There was a suggestion 
in UK data that the raised risk of coronary artery disease in AI 
compared with tamoxifen users diminished over time (p=0.02) 
but no corresponding evidence in US data.
Table 1 Characteristics of study population based on their initial 
exposure in the UK
Tamoxifen AI Total
N 4716 (100) 5289 (100) 10 005 (100)
Age (years)
54–59 911 (19.3) 716 (13.5) 1627 (16.3)
60–69 1850 (39.2) 1972 (37.3) 3822 (38.2)
70+ 1955 (41.5) 2601 (49.2) 4556 (45.5)
Median (IQR) 68 (62–76) 70 (63–79) 69 (62–78)
Year of breast cancer
2002–2005 2267 (48.1) 670 (12.7) 2937 (29.4)
2006–2009 1523 (32.3) 1846 (34.9) 3369 (33.7)
2010–2013 823 (17.5) 2248 (42.5) 3071 (30.7)
2014–2015 103 (2.2) 525 (9.9) 628 (6.3)
BMI (kg/m2)
<18 59 (1.3) 63 (1.2) 122 (1.2)
18–24 1693 (35.9) 1619 (30.6) 3312 (33.1)
25–29 1549 (32.8) 1801 (34.1) 3350 (33.5)
30–34 800 (17) 979 (18.5) 1779 (17.8)
≥35 345 (7.3) 548 (10.4) 893 (8.9)
Missing 270 (5.7) 279 (5.3) 549 (5.5)
Median (IQR) 26 (23–30) 27 (24–31) 27 (24–31)
Smoking status
Never smoker 2423 (51.4) 2517 (47.6) 4940 (49.4)
Current smoker 503 (10.7) 482 (9.1) 985 (9.8)
Ex- smoker 1761 (37.3) 2268 (42.9) 4029 (40.3)
Missing 29 (.6) 22 (.4) 51 (.5)
Alcohol use
Non- drinker 618 (13.1) 613 (11.6) 1231 (12.3)
Current 3320 (70.4) 3628 (68.6) 6948 (69.4)
Ex- drinker 480 (10.2) 715 (13.5) 1195 (11.9)
Missing 298 (6.3) 333 (6.3) 631 (6.3)
Systolic BP
Low/ideal 530 (11.2) 599 (11.3) 1129 (11.3)
Prehigh 1862 (39.5) 2327 (44) 4189 (41.9)
High 2314 (49.1) 2355 (44.5) 4669 (46.7)
Missing 10 (.2) 8 (.2) 18 (.2)
Diastolic BP
Low/ideal 2130 (45.2) 2650 (50.1) 4780 (47.8)
Prehigh 1988 (42.2) 2058 (38.9) 4046 (40.4)
High 588 (12.5) 573 (10.8) 1161 (11.6)
Missing 10 (.2) 8 (.2) 18 (.2)
Index of Multiple 
deprivation category
1 870 (18.4) 962 (18.2) 1832 (18.3)
2 943 (20) 1214 (23) 2157 (21.6)
3 925 (19.6) 1054 (19.9) 1979 (19.8)
4 1052 (22.3) 936 (17.7) 1988 (19.9)
5 926 (19.6) 1122 (21.2) 2048 (20.5)
Missing 0 (0) 1 (0) 1 (0)
CVD- related treatment before index
Statins 1100 (23.3) 1903 (36) 3003 (30)
ACEi 1195 (25.3) 1823 (34.5) 3018 (30.2)
CCB 1195 (25.3) 1764 (33.4) 2959 (29.6)
ARB 493 (10.5) 795 (15) 1288 (12.9)
Antiplatelets 1132 (24) 1639 (31) 2771 (27.7)
Comorbidities before index
RA 138 (2.9) 137 (2.6) 275 (2.7)
Diabetes 462 (9.8) 728 (13.8) 1190 (11.9)
CKD 867 (18.4) 1090 (20.6) 1957 (19.6)
Continued
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Sensitivity analyses
Following modification of study populations, methodology 
and covariates in the UK and USA to make them as similar as 
possible, the risk of all CVDs associated with ever AI compared 
with tamoxifen use were generally in the same direction (online 
supplemental appendix 15). However, the discrepant results for 
HF between the two cohorts persisted. Quantitative bias anal-
yses suggest that unmeasured confounding was unlikely to fully 
explain the large HR for the effect of ever tamoxifen use on MI 
risk (online supplemental appendix 16). Effect estimates in US 
data after additional adjustment for adjuvant radiotherapy were 
similar to primary results (online supplemental appendix 17).
DISCUSSION
Our results suggest that higher observed risks of cardiovascular 
outcomes including coronary artery disease, MI, arrhythmia, 
HF, pericarditis and VHD in AI users compared with tamox-
ifen users are driven by protective associations of tamoxifen with 
CVD outcomes, rather than any cardiotoxic effects of AIs. These 
two population- based cohort studies using UK and US data are 
the first to apply similar methodology to two large popula-
tions to assess the effects of endocrine therapies on a range of 
CVD outcomes in postmenopausal women with breast cancer. 
Both countries’ results suggested a higher risk of several CVD 
outcomes in AI compared with tamoxifen users. However, when 
compared with patients receiving no endocrine therapy, there 
was no raised risk of any CVD outcome in users of either drug 
class, other than VTE in tamoxifen users. Furthermore, tamox-
ifen users had lower risks of coronary artery disease, MI, stroke, 
arrhythmia, pericarditis and VHD than unexposed women. This 
protective effect of tamoxifen might be explained by the drug’s 
effect on lipid levels; previous studies have found tamoxifen to 
reduce cholesterol.5 16
Comparison with other studies
A recent meta- analysis of trials reported an increased risk of 
CVD, excluding VTE, in tamoxifen compared with AI users 
(RR: 1.18, 95% CI 1.05 to 1.33),17 with results suggestive of a 
cardioprotective effect of tamoxifen, consistent with the results 
of this study.10
Most (5/6) previous studies directly comparing the risk 
of MI in AI and tamoxifen users have reported a higher 
risk in AI users, similar to our results (RRs ranged from 
0.99 to 2.02).10 18–22 Two previous trials and five observa-
tional studies have compared MI risk in tamoxifen users 
with non- use/placebo, with 4/7 studies finding a reduced 
risk in tamoxifen users (RRs ranged from 0.20 to 0.83)23–29; 
two analogous studies of AI use versus placebo or non- use 
found no association.28 30 Seven studies (five trials and two 
observational) directly compared the risk of stroke in AI 
and tamoxifen users, but effects in both directions have 
been reported.20 22 31–34 Three out of five studies (one trial 
and four observational) comparing tamoxifen use with non- 
use/placebo found a protective association with stroke, as 
in our study (RRs ranged from 0.52 to 0.81).23 26–28 35 In 
the present analysis, we found AI users to be at lower risk 
of stroke compared with unexposed women; one previous 
study found a similar association but a second reported 
the opposite.28 30 Three previous studies (one trial and two 
observational) have reported results for the comparison 
between AI and tamoxifen use on the risk of HF,10 31 34 for 
which we reported discrepant results between the UK and 
USA. Two reported a higher risk in AI users and the other 
reported no association. The discrepant results in our study 
could be due to residual confounding by variables not avail-
able in both datasets (cancer therapies in the UK and life-
style factors in the USA), or the nature of the data sources 
(routinely collected records in the UK and claims in the 
USA).
Six previous trials compared the risk of VTE in AI and 
tamoxifen users, with five reporting a lower risk in AI 
compared with tamoxifen users (RR ranged from 1.25 
to 0.61), as reported in both UK and US data in this 
study.18 20 22 31 36 37 Six out of eight studies (five trials and 
three observational) also suggested a higher risk in tamoxifen 
users (RRs ranged from 1.64 to 7.10), which is in the same 
direction, but larger than the effect in US data here.
Tamoxifen AI Total
CVD before index
Non- venous CVD 1031 (21.9) 1636 (30.9) 2667 (26.7)
VTE before index 144 (3.1) 324 (6.1) 468 (4.7)
ACEi, Angiotensin- converting- enzyme inhibitors; AI, aromatase inhibitor; ARB, angiotensin 
II receptor blocker; BP, blood pressure; CCB, calcium channel blocker; CKD, Chronic 
kidney disease; CVD, cardiovascular disease; RA, Rhematoid arthritis; VTE, venous 
thromboembolism.
Table 1 Continued
Figure 1 Flow diagrams of study populations in the UK and USA. CPRD, Clinical Practice Research Datalink; GP, general practitioner; HES, Hospital 
Episode Statistics; ER, oestrogen; PR, progesterone.
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Strengths and limitations
A major strength of this study was the use of two large data 
sources with complementary strengths and different limitations. 
We could look for consistency between countries and conduct 
different comparisons, notably between classes and with unex-
posed patients. We were also able to assess the relationships 
between endocrine therapy treatments and a wide range of 
CVD outcomes, rather than the composite and individual CVD 
outcomes in previous studies. We were able to account for several 
important confounders such as potentially cardiotoxic treat-
ments (in US data) and lifestyle factors (in UK data), although 
no confounders materially changed the crude effect estimate 
when adjusted for individually in either the UK or USA (online 
supplemental appendices 18 and 19). As the CPRD broadly 
represents the UK population, and SEER- Medicare includes a 
large, diverse population of older women diagnosed with breast 
cancer, results are generalisable to women diagnosed with ER/
PR+ breast cancer in both the UK, USA and other developed 
populations due to the homogenous indication of endocrine 
therapy worldwide.
In the UK, ER/PR status was not available, but it is likely 
that breast cancers were ER/PR+ as such a diagnosis is a 
prerequisite of being prescribed endocrine therapies. Detail 
on cancer stage and administered therapies were also not 
available in the UK; although the cancer diagnosis is fed back 
from specialists to general practitioners, further detail is 
typically not recorded by the general practitioner and hence 
not available in the CPRD. HES also does not include these 
data; it is not a clinical care database and is rather derived 
from administrative data within the National Health Service. 
Furthermore, CPRD captures prescriptions at the point 
of issue, but we do not know if prescriptions were filled, 
which could lead to potential misclassification of exposure. 
However, descriptive analyses using a 3- month grace period 
to define a continuous prescription indicated that 94% of 
women continued to be prescribed within 1 year of starting, 
85% within 3 years and 74% within 5 years.
In the USA, the proportion of non- initiators of endocrine 
therapy (21%) was similar to the proportion of non- initiators 
reported in a previous study.17 Reasons for non- initiation 
may include frailty, poor CVD preventative care and high 
BMI, introducing possible residual confounding. Although 
quantitative bias analyses suggest it is unlikely that residual 
confounding explains all the large observed protective asso-
ciations between tamoxifen use and several CVD outcomes, 
these associations may be exaggerated, and the smaller 
observed associations between AI use and outcomes could 
be driven by such confounding. Comparisons with non- user 
groups are often more subject to confounding than compari-
sons with groups using similar medications (ie, AI vs tamox-
ifen).38 Caution should be taken in the interpretation of the 
comparisons with non- users, and these results warrant further 
investigation. Furthermore, the US analyses did not include 
those in a managed care programme (Medicare Advantage) 
as these plans do not report claim- level information to Medi-
care, so these data cannot be used for research. Between 
2007 and 2013, this population ranged from approximately 
19%–28% of the total Medicare population, and it is under-
stood that they have lower healthcare utilisation and higher 
quality of care.39–41
CONCLUSION
Among postmenopausal women diagnosed with ER/PR+ 
breast cancer, we found convincing evidence of a higher 
risk of several CVDs in AI compared with tamoxifen users. 
However, our results indicated no excess cardiotoxicities of 
either drug class, other than the known raised risk of VTE 
Table 2 Characteristics of study population based on their initial 
exposure in the USA
Unexposed Tamoxifen AI Total
N 4667 (100) 2286 (100) 15 074 (100) 22 027 (100)
Age at index date (years)
66–74 1538 (33) 897 (39.2) 7505 (49.8) 9940 (45.1)
75–84 1937 (41.5) 994 (43.5) 5894 (39.1) 8825 (40.1)
85+ 1192 (25.5) 395 (17.3) 1675 (11.1) 3262 (14.8)
Median (IQR) 79 (73–85) 77 (72–83) 75 (71–81) 76 (71–82)
Ethnicity*
White 4002 (85.8) 2028 (88.7) 12 782 (84.8) 18 812 (85.4)
Black 360 (7.7) 102 (4.5) 1099 (7.3) 1561 (7.1)
Other 93 (2) 47 (2.1) 335 (2.2) 475 (2.2)
Asian 123 (2.6) 68 (3) 498 (3.3) 689 (3.1)
Hispanic – – – 397 (1.8)
Native American – – – 52 (.2)
Missing – – – 41 (.2)
SEER region
North East 760 (16.3) 283 (12.4) 3320 (22) 4363 (19.8)
South 1023 (21.9) 605 (26.5) 3778 (25.1) 5406 (24.5)
North Central 695 (14.9) 448 (19.6) 1761 (11.7) 2904 (13.2)
West 2157 (46.2) 939 (41.1) 6130 (40.7) 9226 (41.9)
Missing 32 (.7) 11 (.5) 85 (.6) 128 (.6)
Year of breast cancer
2008–2009 1678 (36) 1231 (53.8) 6609 (43.8) 10 247 (46.5)
2010–2011 1473 (31.6) 701 (30.7) 5019 (33.3) 7193 (32.7)
2012–2013 1516 (32.5) 722 (31.6) 5840 (38.7) 8078 (36.7)
Stage of breast cancer
Stage I 3034 (65) 1486 (65) 8379 (55.6) 12 899 (58.6)
Stage II 1275 (27.3) 660 (28.9) 5267 (34.9) 7202 (32.7)
Stage III 358 (7.7) 140 (6.1) 1428 (9.5) 1926 (8.7)
Grade of breast cancer
1 1522 (32.6) 765 (33.5) 4273 (28.3) 6560 (29.8)
2 2071 (44.4) 1109 (48.5) 7350 (48.8) 10 530 (47.8)
3 853 (18.3) 324 (14.2) 2810 (18.6) 3987 (18.1)
Missing 221 (4.7) 88 (3.8) 641 (4.3) 950 (4.3)
Cancer treatments
Taxane 570 (12.2) 162 (7.1) 2415 (16) 3147 (14.3)
Anthracyclines 259 (5.5) 68 (3) 820 (5.4) 1147 (5.2)
Trastuzumab 226 (4.8) 39 (1.7) 687 (4.6) 952 (4.3)
Other treatment 753 (16.1) 244 (10.7) 2992 (19.8) 3989 (18.1)
Comorbidities
RA 185 (4) 103 (4.5) 547 (3.6) 835 (3.8)
CKD 383 (8.2) 155 (6.8) 1113 (7.4) 1651 (7.5)
Hypertension 3426 (73.4) 1612 (70.5) 11 113 (73.7) 16 151 (73.3)
Diabetes 1313 (28.1) 598 (26.2) 4545 (30.2) 6456 (29.3)
CVD- related treatment before index
Statins 1778 (38.1) 948 (41.5) 6988 (46.4) 9714 (44.1)
Hypertensives 169 (3.6) 83 (3.6) 577 (3.8) 829 (3.8)
ACEi 962 (20.6) 477 (20.9) 3251 (21.6) 4690 (21.3)
CCB 850 (18.2) 364 (15.9) 2696 (17.9) 3910 (17.8)
ARB 593 (12.7) 255 (11.2) 2063 (13.7) 2911 (13.2)
Past CVD
Non- venous CVD 2989 (64) 1281 (56) 8896 (59) 13 166 (59.8)
VTE 162 (3.5) 31 (1.4) 385 (2.6) 578 (2.6)
*Cell numbers within ethnicity suppressed due to some cells containing numbers <11.
ACEi, Angiotensin- converting- enzyme inhibitors; AI, aromatase inhibitor; ARB, angiotensin II 
receptor blocker; CCB, calcium channel blocker; CKD, Chronic kidney disease; CVD, cardiovascular 
disease; RA, Rheumatoid arthritis; SEER, Surveillance, Epidemiology, and End Results; VTE, venous 
thromboembolism.
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Figure 2 Adjusted HRs for the association between ever AI use compared with ever tamoxifen use and the risk of a range of clinical CVD outcomes 
in the UK and USA. *UK results adjusted for the following covariates at baseline: for age (54–59, 60–69 and 70+ years); smoking status (non- smoker, 
current smoker and ex- smoker); BMI (underweight/healthy weight, overweight and obese); alcohol status (non- drinker, current drinker and ex- 
drinker); IMD score (levels 1–5 based on GP level IMD data); use of statins; use of ACE inhibitors; use of calcium channel blockers; use of angiotensin 
II receptor blockers; diabetes; chronic kidney disease; rheumatoid arthritis; systolic blood pressure (low/normal, prehigh and high); diastolic blood 
pressure (low/normal, prehigh and high); history of non- venous CVD year of breast cancer diagnosis; time since index (0–1 years, 1–3 years, 3–5 
years and 5+ years); and current year. US results adjusted for year of breast cancer diagnosis (2007–2013); age at index date (66–74, 75–84 and 
85+ years); race (white, black Asian, Hispanic, Native American and other); SEER region (North East, South, North Central and West); breast cancer 
stage (1–3); breast cancer grade (1–3); time since index date (0–1years, 1–3 years, 3–5 years and 5+ years); current calendar year; use of taxanes, 
anthracycline, trastuzumab, other systemic cancer treatments, statins, antihypertensive drugs, ACE inhibitors, calcium channel blockers, angiotensin 
receptor blockers; diagnosis of rheumatoid arthritis, chronic kidney disease, hypertension, diabetes, VTE and non- venous CVD. **Numbers of events 
for each outcome in the AI and tamoxifen groups are shown in online supplemental appendices 11 and 12. AI, aromatase inhibitor; BMI, body 
mass index; CVD, cardiovascular disease; DVT, deep vein thrombosis; HF, heart failure; MI, myocardial infarction; PE, pulmonary embolism; PVD, 
peripheral vascular disease; SCA, sudden cardiac arrest; SEER, Surveillance, Epidemiology, and End Results; VHD, valvular heart disease; VTE, venous 
thromboembolism.
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Figure 3 Adjusted HRs, events and crude rate per 1000 person- years for the association between ever exposure to endocrine therapy and a range 
of clinical CVD outcomes in the USA. *Adjusted for year of breast cancer diagnosis (2007–2013); age at index date (66–74, 75–84 and 85+ years); 
race (white, black Asian, Hispanic, Native American and other); SEER region (North East, South, North Central and West); breast cancer stage (1–3); 
breast cancer grade (1–3); time since index date (0–1 year, 1–3 years, 3–5 years and 5+ years); current calendar year; use of taxanes, anthracyclines, 
trastuzumab, other systemic cancer treatments, statins, antihypertensive drugs, ACE inhibitors, calcium channel blockers, angiotensin receptor blockers; 
and diagnosis of rheumatoid arthritis, chronic kidney disease, hypertension, diabetes, VTE and non- venous CVD. **Events and follow- up suppressed if 
number of events ≤11. CVD, cardiovascular disease; DVT, deep vein thrombosis; HF, heart failure; MI, myocardial infarction; PE, pulmonary embolism; 
PVD, peripheral vascular disease; SCA, sudden cardiac arrest; SEER, Surveillance, Epidemiology, and End Results; VHD, valvular heart disease; VTE, 
venous thromboembolism.
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with tamoxifen use. There was no evidence of raised risk of 
any specific CVD with AI use, including in stratified results 
restricted to those with other prior CVDs, suggesting that 
a history of CVD is unlikely to be an important contraindi-
cation for prescription of an AI. Our results contribute to 
the evidence base regarding the risk–benefit balance of endo-
crine therapies with respect to cancer survival and cardiovas-
cular outcomes and ultimately can help identify subgroups 
of postmenopausal women who are likely to benefit from 
tamoxifen over AIs.
Key messages
What is already known on this subject?
 ► Women with oestrogen or progesterone receptor positive 
breast cancer typically receive endocrine therapies, either 
tamoxifen or aromatase inhibitors (AIs), to reduce cancer 
recurrence risk. Recent studies have suggested raised 
cardiovascular risks in AI compared with tamoxifen users, but 
it is unclear whether this reflects cardiotoxicities of AIs or a 
protective effect of tamoxifen.
What might this study add?
 ► Among postmenopausal women with breast cancer, we 
found a higher risk of several cardiovascular diseases in AI 
compared with tamoxifen users across two countries, which 
appeared to be driven by protective effects of tamoxifen, 
rather than toxic effects of AIs. We also found the known 
higher venous thromboembolism risk in tamoxifen users.
How might this impact on clinical practice?
 ► Previous evidence could lead to reduced uptake of AIs among 
those at a high risk of cardiovascular disease. However, there 
is no current evidence to suggest that the cardiovascular 
benefits of tamoxifen outweigh the far superior effect that 
AIs have on breast cancer recurrence in this population, and 
there is no higher cardiovascular risk when prescribing AIs to 
these patients. These results should allay any concerns about 
postulated cardiotoxicities of AIs, and modifications to clinical 
practice could reduce the risk of patients being prescribed 
inappropriate endocrine therapies.
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